

The EarliPoint™ Evaluation for Autism

EYE-TRACKING TECHNOLOG

identifies and assesses young children with autism

SOCIAL DISABILI

Measures the 3 core domains of autism:


VERBAL ABI **NON-VERBAL LEARNII**

Studied in 1,500+ children

Correctly identifies

> children with autism





FEASIBILIT STUDIES 1,089 children

Prospective, consecutivelyenrolled, broad spectrum double-blinded

DISCOVERY COHORT

81.9% Sensitivity 89.9% Specificity




REPLICATION COHORT

80.6% Sensitivity 82.3% Specificity

INDEX ACCURACY

Captured from the variance of the reference standard:



FEASIBILITY STUDIES CONCLUSION

In two large studies of 2-year-old children, objective eye-tracking-based assays accurately quantified diagnostic status and symptom crucial step towards community-wide, equitable early identification of autism, a key factor in promoting optimal long-term outcomes in all children.



DIAGNOSTIC ACCURACY

78.0% Sensitivity 85.4% Specificity

Area Under the Curve (AUC) = 0.902

STUD 505 children

Multi-site, prospective, doubleblind within subject comparison

INDEX **ACCURACY**

Captured from the variance

74.1% Social Disability

88.8% Verbal Ability

PIVOTAL STUDY CONCLUSION

In 16-30-month-old pediatric patients, neurodevelopmental assessment via eye-tracking can Professional medical organizations¹ and federal



Earlitec Diagnostics, Inc. 755 Commerce Drive, Suite 700 Decatur, GA 30030

info@earlitecdx.com www.earlitecdx.com